The Effect of Vaccine Type and SARS-CoV-2 Lineage on Commercial SARS-CoV-2 Serologic and Pseudotype Neutralization Assays in mRNA Vaccine Recipients.
immunogenicity
mRNA vaccines
serology
Journal
Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614
Informations de publication
Date de publication:
27 04 2022
27 04 2022
Historique:
pubmed:
22
3
2022
medline:
30
4
2022
entrez:
21
3
2022
Statut:
ppublish
Résumé
The use of anti-spike (S) serologic assays as surrogate measurements of SARS-CoV-2 vaccine induced immunity will be an important clinical and epidemiological tool. The characteristics of a commercially available anti-S antibody assay (Roche Elecsys anti-SARS-CoV-2 S) were evaluated in a cohort of vaccine recipients. Levels were correlated with pseudotype neutralizing antibodies (NAb) across SARS-CoV-2 variants. We recruited adults receiving a two-dose series of mRNA-1273 or BNT162b2 and collected serum at scheduled intervals up to 8 months post-first vaccination. Anti-S and NAb levels were measured, and correlation was evaluated by (i) vaccine type and (ii) SARS-CoV-2 variant (wild-type, Alpha, Beta, Gamma, and three constructs Day 146*, Day 152*, and RBM-2). Forty-six mRNA vaccine recipients were enrolled. mRNA-1273 vaccine recipients had higher peak anti-S and NAb levels compared with BNT162b2 (
Identifiants
pubmed: 35311584
doi: 10.1128/spectrum.00211-22
pmc: PMC9045317
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Vaccines, Synthetic
0
mRNA Vaccines
0
2019-nCoV Vaccine mRNA-1273
EPK39PL4R4
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0021122Subventions
Organisme : NIGMS NIH HHS
ID : T32 GM007753
Pays : United States
Organisme : NCEZID CDC HHS
ID : U01 CK000633
Pays : United States
Références
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
J Virol Methods. 2021 Nov;297:114271
pubmed: 34461153
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Cell. 2021 May 13;184(10):2605-2617.e18
pubmed: 33831372
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
JAMA. 2021 Oct 19;326(15):1533-1535
pubmed: 34459863
Clin Lab Med. 2022 Mar;42(1):111-128
pubmed: 35153045
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
N Engl J Med. 2021 Nov 4;385(19):1774-1785
pubmed: 34551225
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033172
Cell. 2020 Oct 29;183(3):739-751.e8
pubmed: 32991842
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Science. 2021 Sep 17;373(6561):1372-1377
pubmed: 34385356
Infection. 2021 Feb;49(1):75-82
pubmed: 32827125
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Science. 2022 Jan 21;375(6578):eabl6251
pubmed: 34855508
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Microbiol Spectr. 2021 Sep 3;9(1):e0034121
pubmed: 34346750
N Engl J Med. 2020 Dec 3;383(23):2291-2293
pubmed: 33176080
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246